临床前CDMO研发筛选相关化合物

CDMO是Contract Development and Manufacturing Organization的缩写，即合同定制研发生产组织。它是一种为制药企业及生物技术公司提供医药（特别是创新药）工艺研发及制备、工艺优化、放大生产、注册和验证批生产以及商业化生产等定制服务的机构. 在传统代工基础上增加了研发和工艺优化能力，是高技术壁垒的工艺研发能力与规模生产能力的深度结合. 1, 工艺开发与优化：创新性合成路线设计、工艺参数优化. 2, 中试放大：实验室工艺向规模化生产的转化 3, 注册批生产：支持客户新药申报的验证批生产. 4, 商业化生产：药品上市后的大规模生产供应. 全球医药CDMO行业保持较高景气度。根据弗若斯特沙利文预测：2026年全球CDMO市场规模：预计达1,189亿美元 2033年全球CDMO市场规模：预计达3,385亿美元. CDMO作为医药产业链专业化分工的产物，已经从单纯的CMO代工模式升级为"研发+生产"一体化的高附加值服务。当前，在多肽、ADC、CGT等新型药物赛道的驱动下，全球及中国CDMO市场保持高速增长。中国CDMO企业凭借完整的供应链体系、工程师红利和一体化服务能力，全球市占率有望持续提升，行业正从"成本优势"竞争迈向"体系优势"竞争的新阶段。
如有产品调研服务, 请致函联系我们

客户展示

临床前CDMO研发化合物筛选

CAS: 50-63-5

Chloroquine diphosphate

中文名称: 磷酸氯喹
CAS号:50-63-5
分子式: C18H26ClN3.2H3O4P 分子量: 515.86
产品形式: diphosphate
研发状态: Not yet recruiting
研发用途: Sarcoidosis Pulmonary
研究机构: Hospices Civils de Lyon
研发日期: April 1 2024
研发阶段: Phase 4
Chloroquine diphosphate is a 4-aminoquinoline anti-malarial and anti-rheumatoid agent, also acting as an ATM activator. Chloroquine is also an inhibitor of toll-like receptors (TLRs).

CAS: 50-53-3

Chlorpromazine

中文名称:氯丙嗪
CAS号:50-53-3
分子式: C17H19ClN2S 分子量: 318.86
产品形式: Free Base
研发状态: Recruiting
研发用途: Intellectual Disability
研究机构: University of Plymouth; Peninsula Clinical Trials Unit
研发日期: December 19 2023
研发阶段: --
Chlorpromazine (CPZ) is a low-potency typical antipsychotic agent that is used to treat psychotic disorders such as schizophrenia. Chlorpromazine (CPZ) inhibits 5-HT(2A) receptor and dopamine D2 in vitro. Chlorpromazine (CPZ) also inhibits sodium channel and blocks HERG potassium channels with IC50 of 21.6 μM.

CAS: 5051-62-7

Guanabenz

中文名称:胍那苄
CAS号:5051-62-7
分子式: C8H8Cl2N4 分子量: 231.08
产品形式: Free Base
研发状态: Recruiting
研发用途: Cancer
研究机构: Peking University Cancer Hospital & Institute; Peking University Health Science Center
研发日期: September 20 2024
研发阶段: Early Phase 1
Guanabenz (GBZ, GA, Wytensin, Wy-8678,BR-750) is an orally active central alpha 2-adrenoceptor (α2 adrenergic receptor) agonist with antihypertensive action.

CAS: 50-44-2

Mercaptopurine (6-MP)

中文名称:6-巯基嘌呤
CAS号:50-44-2
分子式: C5H4N4S 分子量: 152.18
产品形式: free base
研发状态: Completed
研发用途: Acute Lymphoblastic Leukemia Pediatric; Adverse Drug Event
研究机构: Cipherome Inc.; Stanford University
研发日期: February 23 2021
研发阶段: --
Mercaptopurine(6-MP) is a widely used antileukemic agent and immunosuppressive drug that inhibits de novo purine synthesis through incorporation of thiopurine methyltransferase metabolites into DNA and RNA.

CAS: 503612-47-3

Apixaban (BMS 562247-01)

中文名称:阿哌沙班
CAS号:503612-47-3
分子式: C25H25N5O4 分子量: 459.50
产品形式: free base
研发状态: Not yet recruiting
研发用途: Healthy Volunteer
研究机构: International Bio service
研发日期: August 26 2024
研发阶段: Phase 1
Apixaban (BMS 562247-01) is a highly selective, reversible inhibitor of Factor Xa with Ki of 0.08 nM and 0.17 nM in human and rabbit, respectively.

CAS: 50-35-1

Thalidomide (K17)

中文名称:沙利度胺
CAS号:50-35-1
分子式: C13H10N2O4 分子量: 258.23
产品形式: free base
研发状态: Completed
研发用途: Transfusion-dependent Beta-Thalassemia
研究机构: Blood Care Clinic; Khyber Medical University Peshawar
研发日期: January 25 2022
研发阶段: Phase 3
Thalidomide (K17) was introduced as a sedative drug, immunomodulatory agent and also is investigated for treating symptoms of many cancers. Thalidomide inhibits cereblon (CRBN), a part of the cullin-4 E3 ubiquitin ligase complex CUL4-RBX1-DDB1.